|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:approvalYear
|
1994
|
|
gptkbp:ATCCode
|
A10BA02
|
|
gptkbp:bioavailability
|
50-60%
|
|
gptkbp:brand
|
gptkb:Diabex
gptkb:Diaformin
gptkb:Metfogamma
gptkb:Metforal
gptkb:Riomet
gptkb:Siofor
gptkb:Dianben
gptkb:Glifor
gptkb:Obimet
gptkb:Glucophage_XR
gptkb:Fortamet
gptkb:Glucophage
gptkb:Glumetza
|
|
gptkbp:CASNumber
|
657-24-9
|
|
gptkbp:contraindication
|
metabolic acidosis
renal impairment
hypersensitivity to metformin
|
|
gptkbp:drugClass
|
antidiabetic agent
biguanide
|
|
gptkbp:drugInteraction
|
gptkb:beer
cimetidine
iodinated contrast agents
|
|
gptkbp:eliminationHalfLife
|
4-8.7 hours
|
|
gptkbp:excretion
|
renal
|
|
gptkbp:hasInChIKey
|
gptkb:XZWYZXLIPXDOLR-UHFFFAOYSA-N
|
|
gptkbp:hasMolecularFormula
|
C4H11N5
|
|
gptkbp:hasSMILES
|
CN(C)C(=N)N=C(N)N
|
|
gptkbp:hasUNII
|
9100L32L2N
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
DB00928
|
|
gptkbp:indication
|
gptkb:type_2_diabetes_mellitus
gptkb:polycystic_ovary_syndrome_(off-label)
|
|
gptkbp:isApprovedDrug
|
gptkb:WHO_Model_List_of_Essential_Medicines
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
decreases hepatic glucose production
increases insulin sensitivity
|
|
gptkbp:metabolism
|
not metabolized
|
|
gptkbp:molecularWeight
|
129.164
|
|
gptkbp:name
|
gptkb:Metformin
|
|
gptkbp:originatedIn
|
biguanide class
|
|
gptkbp:pregnancyCategory
|
B (US)
|
|
gptkbp:proteinBinding
|
negligible
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL1431
gptkb:D01841
gptkb:DB00928
6801
4091
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gastrointestinal upset
lactic acidosis (rare)
|
|
gptkbp:synonym
|
1,1-dimethylbiguanide
dimethylbiguanide
|
|
gptkbp:target
|
gptkb:mitochondrial_respiratory_chain_complex_I
gptkb:AMP-activated_protein_kinase_(AMPK)
|
|
gptkbp:bfsParent
|
gptkb:azacitidine
|
|
gptkbp:bfsLayer
|
8
|